An assessment of the prescribing preferences of Irish dermatology consultants for the treatment of severe psoriasis in the setting of a cancer diagnosis

Simple item page
dc.check.date2026-10-01en
dc.check.infoAccess to this article is restricted until 12 months after publication by request of the publisheren
dc.contributor.authorBowe, Stephanieen
dc.contributor.authorMurphy, Michelleen
dc.contributor.authorBourke, Johnen
dc.contributor.authorRyan, Caitrionaen
dc.date.accessioned2025-11-03T15:20:47Z
dc.date.available2025-11-03T15:20:47Z
dc.date.issued2025-10-01en
dc.description.abstractAim: We aimed to investigate the systemic and biologic agent choices of dermatologists in Ireland for those patients with psoriasis and a cancer diagnosis. Methods: An electronic questionnaire was circulated to the Irish Association of Dermatology members using the survey platform, Jotform, between December 2023—June 2025. Results: In total there were 27 responses. Methotrexate was selected most commonly for all scenarios > 5 years remission. In all clinical scenarios, fumaric acid esters were the least frequently selected agents. In general, tumour necrosis factor-alpha inhibitors were the next least commonly selected. Apremilast was selected most commonly for a current malignancy of stage 1 breast cancer (26%), lymphoma (22%) and metastatic RCC (30%). Conclusion: In general, systemic and biologic agents are used by Irish dermatologists in the setting of psoriasis and cancer.en
dc.description.statusPeer revieweden
dc.description.versionAccepted Versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.citationBowe, S., Murphy, M., Bourke, J. and Ryan, C. (2025) 'An assessment of the prescribing preferences of Irish dermatology consultants for the treatment of severe psoriasis in the setting of a cancer diagnosis', Irish Journal of Medical Science, pp.1-8. https://doi.org/10.1007/s11845-025-04113-0en
dc.identifier.doi10.1007/s11845-025-04113-0en
dc.identifier.eissn1863-4362en
dc.identifier.endpage8en
dc.identifier.issn0021-1265en
dc.identifier.journaltitleIrish Journal of Medical Scienceen
dc.identifier.startpage1en
dc.identifier.urihttps://hdl.handle.net/10468/18142
dc.language.isoenen
dc.publisherSpringer Natureen
dc.relation.ispartofIrish Journal of Medical Scienceen
dc.rights© 2025, the Authors, under exclusive licence to Royal Academy of Medicine in Ireland. Published by Springer Nature. This version of the paper has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: https://doi.org/10.1007/s11845-025-04113-0en
dc.subjectSystemic and biologic agent choicesen
dc.subjectDermatologyen
dc.subjectIrelanden
dc.subjectPsoriasisen
dc.subjectCancer diagnosisen
dc.titleAn assessment of the prescribing preferences of Irish dermatology consultants for the treatment of severe psoriasis in the setting of a cancer diagnosisen
dc.typeArticle (peer-reviewed)en
dc.typejournal-articleen
Files
Original bundle
Now showing 1 - 2 of 2
Thumbnail Image
Name:
IJMS-D-25-01938.pdf
Size:
5.89 MB
Format:
Adobe Portable Document Format
Description:
Accepted Version
Thumbnail Image
Name:
11845_2025_4113_MOESM1_ESM.pdf
Size:
98.9 KB
Format:
Adobe Portable Document Format
Description:
Supplementary Information
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medicine - Journal Articles